Phaseline

Companies › EyeBiotech

EyeBiotech: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 5 Phase 2; Ophthalmology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Remigromig (EYE103)
humanized antibody
–Phase 2Diabetic Macular Edema (DME); Neovascular Age-Related Macular Degeneration (NVAMD)Jan 2027
Tiespectus (EYE201/MK-8748)–Phase 2Macular DegenerationJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06957080Remigromig (EYE103)Phase 2Diabetic Macular Edema (DME)OphthalmologyJan 2027
NCT06571045Remigromig (EYE103)Phase 2Diabetic Macular Edema (DME)OphthalmologyDec 2027
NCT07205887Remigromig (EYE103)Phase 2Neovascular Age-Related Macular Degeneration (NVAMD)OphthalmologyJun 2028
NCT07440225Tiespectus (EYE201/MK-8748)Phase 2Macular DegenerationOphthalmologyJun 2028
NCT07496567Tiespectus (EYE201/MK-8748)Phase 2Macular DegenerationOphthalmologyJul 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

AiViva BioPharma Adverum Biotechnologies BioDlink Biopharm EyePoint Pharmaceuticals Intra-IMMUSG Pte

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.